Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Amgen Securities Litigation

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Amgen Securities Litigation:

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

IN RE AMGEN INC. SECURITIES LITIGATION

 

 

 

Civil Action No. 1:23-cv-02138 (JPC) (HJR)

CLASS ACTION

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION

TO: ALL PERSONS THAT PURCHASED OR OTHERWISE ACQUIRED AMGEN INC. (“AMGEN” OR THE “COMPANY”) COMMON STOCK BETWEEN JULY 29, 2020 AND APRIL 27, 2022, INCLUSIVE (“CLASS” OR “CLASS MEMBER”), WHO WERE DAMAGED THEREBY

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

YOU ARE HEREBY NOTIFIED that a hearing will be held on March 2, 2027, at 10:00 a.m., before Magistrate Judge Henry J. Ricardo at the United States District Court, Southern District of New York, in Courtroom 21D of the Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, New York, NY 10007, to determine whether: (1) the proposed settlement (the “Settlement”) of the above-captioned action (the “Action”) as set forth in the Stipulation of Settlement (“Stipulation”)1 for $74,000,000 in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Action with prejudice; (3) to award Lead Counsel attorneys’ fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action (“Notice”), which is discussed below) and to grant Lead Plaintiff an award pursuant to 15 U.S.C. §78u-4(a)(4) in connection with its representation of the Class, and, if so, in what amounts; and (4) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.

The Court may decide to conduct the Settlement Hearing by video or telephonic conference, or otherwise allow Class Members to appear remotely at the hearing, without further written notice to the Class. In order to determine whether the date and time of the Settlement Hearing has changed, or whether it will be conducted by telephone or video, it is important that you monitor the Court’s docket and the Settlement website, www.AmgenSecuritiesSettlement.com, before making any plans to attend the Settlement Hearing. Updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website, www.AmgenSecuritiesSettlement.com. Also, if the Court requires or allows Class Members to participate in the Settlement Hearing by remote means, the information for accessing the hearing will be posted to the Settlement website.

IF YOU PURCHASED OR OTHERWISE ACQUIRED AMGEN COMMON STOCK BETWEEN JULY 29, 2020 AND APRIL 27, 2022, INCLUSIVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THE ACTION.

To share in the distribution of the Net Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form (“Proof of Claim”) by mail (postmarked no later than February 9, 2027) or electronically via the website (no later than February 9, 2027). Failure to submit your Proof of Claim by February 9, 2027, may subject your claim to rejection and may preclude you from receiving any of the recovery in connection with the Settlement of the Action. If you are a Member of the Class and do not request exclusion from the Class, you will be bound by the Settlement and any judgment and release entered in the Action, including, but not limited to, the Judgment, whether or not you submit a Proof of Claim.

If you have not received a copy of the Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement), and a Proof of Claim, you may obtain these documents, as well as a copy of the Stipulation (which, among other things, contains definitions for the defined terms used in this Summary Notice) and other Settlement documents, online at www.AmgenSecuritiesSettlement.com, or by writing to or calling:

Amgen Securities Settlement

Claims Administrator

c/o Verita Global

P.O. Box 301133

Los Angeles, CA 90030-1133

info@AmgenSecuritiesSettlement.com

1-888-808-7928

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim, may be made to Lead Counsel:

ROBBINS GELLER RUDMAN & DOWD LLP

Theodore J. Pintar

655 West Broadway, Suite 1900

San Diego, CA 92101

Telephone: 1-800-449-4900

settlementinfo@rgrdlaw.com

IF YOU DESIRE TO BE EXCLUDED FROM THE CLASS, YOU MUST SUBMIT A REQUEST FOR EXCLUSION SUCH THAT IT IS POSTMARKED OR RECEIVED BY FEBRUARY 9, 2027, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE. ALL CLASS MEMBERS WILL BE BOUND BY THE SETTLEMENT EVEN IF THEY DO NOT SUBMIT A TIMELY PROOF OF CLAIM.

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT, THE PLAN OF ALLOCATION, THE REQUEST BY LEAD COUNSEL FOR AN AWARD OF ATTORNEYS’ FEES NOT TO EXCEED ONE-THIRD OF THE $74,000,000 SETTLEMENT AMOUNT AND EXPENSES NOT TO EXCEED $500,000, PLUS INTEREST ON BOTH AMOUNTS, AND/OR THE REQUEST FOR AN AWARD TO LEAD PLAINTIFF NOT TO EXCEED $25,000 IN CONNECTION WITH ITS REPRESENTATION OF THE CLASS. ANY OBJECTIONS MUST BE FILED WITH THE COURT AND RECEIVED BY LEAD COUNSEL AND DEFENDANTS’ COUNSEL BY FEBRUARY 9, 2027, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: October 21, 2026

BY ORDER OF THE COURT

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

1 The Stipulation can be viewed and/or obtained at www.AmgenSecuritiesSettlement.com.

Media gallery